Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
HRT's Cash-to-Debt is ranked lower than
95% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. HRT: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
HRT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 3.33 Max: No Debt
Current: 0.05
Equity-to-Asset 0.47
HRT's Equity-to-Asset is ranked lower than
67% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. HRT: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
HRT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.86 Max: 0.96
Current: 0.47
0.39
0.96
Piotroski F-Score: 3
Altman Z-Score: 2.08
Beneish M-Score: -2.88
WACC vs ROIC
7.70%
-4.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -2.54
HRT's Operating Margin % is ranked lower than
58% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. HRT: -2.54 )
Ranked among companies with meaningful Operating Margin % only.
HRT' s Operating Margin % Range Over the Past 10 Years
Min: -15.6  Med: 2.74 Max: 16.65
Current: -2.54
-15.6
16.65
Net Margin % -3.97
HRT's Net Margin % is ranked lower than
59% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. HRT: -3.97 )
Ranked among companies with meaningful Net Margin % only.
HRT' s Net Margin % Range Over the Past 10 Years
Min: -29.73  Med: 1.69 Max: 11.2
Current: -3.97
-29.73
11.2
ROE % -11.48
HRT's ROE % is ranked lower than
63% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. HRT: -11.48 )
Ranked among companies with meaningful ROE % only.
HRT' s ROE % Range Over the Past 10 Years
Min: -48.14  Med: 2.28 Max: 16.37
Current: -11.48
-48.14
16.37
ROA % -5.51
HRT's ROA % is ranked lower than
56% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. HRT: -5.51 )
Ranked among companies with meaningful ROA % only.
HRT' s ROA % Range Over the Past 10 Years
Min: -33.69  Med: 2 Max: 14.81
Current: -5.51
-33.69
14.81
ROC (Joel Greenblatt) % -5.09
HRT's ROC (Joel Greenblatt) % is ranked lower than
55% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. HRT: -5.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HRT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -31.98  Med: 5.02 Max: 34.52
Current: -5.09
-31.98
34.52
3-Year Revenue Growth Rate 1.20
HRT's 3-Year Revenue Growth Rate is ranked lower than
62% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. HRT: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HRT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25.3  Med: 1.6 Max: 34.6
Current: 1.2
-25.3
34.6
3-Year EPS without NRI Growth Rate -31.10
HRT's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. HRT: -31.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HRT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.1  Med: 6.7 Max: 162.1
Current: -31.1
-44.1
162.1
GuruFocus has detected 3 Warning Signs with Arrhythmia Research Technology Inc $HRT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HRT's 10-Y Financials

Financials (Next Earnings Date: 2017-05-12 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HRT Guru Trades in Q1 2016

Jim Simons 92,500 sh (+1.65%)
» More
Q2 2016

HRT Guru Trades in Q2 2016

Jim Simons 94,000 sh (+1.62%)
» More
Q3 2016

HRT Guru Trades in Q3 2016

Jim Simons 94,500 sh (+0.53%)
» More
Q4 2016

HRT Guru Trades in Q4 2016

Jim Simons 94,700 sh (+0.21%)
» More
» Details

Insider Trades

Latest Guru Trades with HRT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:LLIT, OTCPK:CRVW, AMEX:XTNT, OTCPK:ABMT, NAS:EVAR, OTCPK:NIMU, OTCPK:ZYXI, OTCPK:SMLR, OTCPK:GIDYL, NAS:DYNT, NAS:AMDA, OTCPK:PYNGF, OTCPK:NUMD, OTCPK:PBIO, NAS:AHPI, NAS:PHMD, OTCPK:MRIC, OTCPK:ACAR, OTCPK:GCHIF, OTCPK:AROSF » details
Arrhythmia Research Technology is a contract manufacturing organization. It produces medical device technologies requiring precision machining and injection molding.

Arrhythmia Research Technology was incorporated under the laws of the State of Louisiana in 1981 and reincorporated under the laws of the State of Delaware in 1987. It completed an initial public offering in 1988. The Company through its wholly-owned subsidiary is a manufacturer specializing in plastic molding, precision metal and plastics machining and precious metal coating. It is also engaged in the development and licensing of signal averaged electrocardiography (SAECG) software, through its Predictor brand. The Company's technologies used in analyzing high resolution heart signals. Its Predictor software is used in research and clinical environments to diagnose the risk of certain heart arrhythmias. The Company invests in research and development, product support and sales efforts. The Company sells its services to its customers to provide product life cycle support to their product manufacturing needs. It provides complex value added US based manufacturing capabilities in injection molding, machining and plating/coating, mold making, maintenance and repair. The Company's operations are subject to government regulations which establish compliance standards and result in costs to comply in order to participate in certain markets.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 455.56
HRT's Price-to-Owner-Earnings is ranked lower than
98% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. HRT: 455.56 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HRT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.24  Med: 30.16 Max: 492.22
Current: 455.56
4.24
492.22
PB Ratio 1.76
HRT's PB Ratio is ranked higher than
74% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. HRT: 1.76 )
Ranked among companies with meaningful PB Ratio only.
HRT' s PB Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.19 Max: 6.17
Current: 1.76
0.26
6.17
PS Ratio 0.59
HRT's PS Ratio is ranked higher than
91% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. HRT: 0.59 )
Ranked among companies with meaningful PS Ratio only.
HRT' s PS Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.63 Max: 4.6
Current: 0.59
0.2
4.6
Price-to-Free-Cash-Flow 37.61
HRT's Price-to-Free-Cash-Flow is ranked lower than
61% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 29.73 vs. HRT: 37.61 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HRT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.17  Med: 20.85 Max: 657.5
Current: 37.61
3.17
657.5
Price-to-Operating-Cash-Flow 7.87
HRT's Price-to-Operating-Cash-Flow is ranked higher than
89% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. HRT: 7.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HRT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.78  Med: 10.02 Max: 41.93
Current: 7.87
1.78
41.93
EV-to-EBIT -28.96
HRT's EV-to-EBIT is ranked lower than
99.99% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. HRT: -28.96 )
Ranked among companies with meaningful EV-to-EBIT only.
HRT' s EV-to-EBIT Range Over the Past 10 Years
Min: -210.5  Med: 11 Max: 223.8
Current: -28.96
-210.5
223.8
EV-to-EBITDA 15.40
HRT's EV-to-EBITDA is ranked higher than
55% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. HRT: 15.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
HRT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17  Med: 6.9 Max: 33.3
Current: 15.4
-17
33.3
Current Ratio 1.12
HRT's Current Ratio is ranked lower than
84% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. HRT: 1.12 )
Ranked among companies with meaningful Current Ratio only.
HRT' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.77 Max: 10.41
Current: 1.12
1.04
10.41
Quick Ratio 0.58
HRT's Quick Ratio is ranked lower than
90% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. HRT: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
HRT' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 2.58 Max: 8.09
Current: 0.58
0.58
8.09
Days Inventory 55.28
HRT's Days Inventory is ranked higher than
85% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. HRT: 55.28 )
Ranked among companies with meaningful Days Inventory only.
HRT' s Days Inventory Range Over the Past 10 Years
Min: 45.54  Med: 59.83 Max: 72.83
Current: 55.28
45.54
72.83
Days Sales Outstanding 44.13
HRT's Days Sales Outstanding is ranked higher than
81% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. HRT: 44.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
HRT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.92  Med: 53.82 Max: 65.94
Current: 44.13
43.92
65.94
Days Payable 43.42
HRT's Days Payable is ranked lower than
65% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. HRT: 43.42 )
Ranked among companies with meaningful Days Payable only.
HRT' s Days Payable Range Over the Past 10 Years
Min: 15.71  Med: 35.58 Max: 49.86
Current: 43.42
15.71
49.86

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
HRT's 3-Year Dividend Growth Rate is ranked lower than
88% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. HRT: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
HRT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
5-Year Yield-on-Cost % 1.20
HRT's 5-Year Yield-on-Cost % is ranked lower than
67% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. HRT: 1.20 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HRT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.12  Med: 1.2 Max: 4.09
Current: 1.2
0.12
4.09
3-Year Average Share Buyback Ratio -1.20
HRT's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. HRT: -1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HRT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.4 Max: 6.9
Current: -1.2
-1.2
6.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.76
HRT's Price-to-Tangible-Book is ranked higher than
81% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. HRT: 1.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HRT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.38  Med: 1.2 Max: 10.87
Current: 1.76
0.38
10.87
Price-to-Intrinsic-Value-Projected-FCF 8.54
HRT's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
87% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. HRT: 8.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HRT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.26  Med: 0.8 Max: 8.73
Current: 8.54
0.26
8.73
Price-to-Median-PS-Value 0.94
HRT's Price-to-Median-PS-Value is ranked higher than
60% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. HRT: 0.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HRT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.15 Max: 17.27
Current: 0.94
0.38
17.27
Earnings Yield (Greenblatt) % -3.45
HRT's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. HRT: -3.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HRT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.45  Med: 5.15 Max: 25.9
Current: -3.45
-3.45
25.9
Forward Rate of Return (Yacktman) % -8.00
HRT's Forward Rate of Return (Yacktman) % is ranked lower than
87% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.01 vs. HRT: -8.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HRT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21  Med: -7.1 Max: 38.8
Current: -8
-21
38.8

More Statistics

Revenue (TTM) (Mil) $19.58
EPS (TTM) $ -0.27
Beta0.78
Short Percentage of Float0.89%
52-Week Range $3.47 - 4.83
Shares Outstanding (Mil)2.82
» More Articles for HRT

Headlines

Articles On GuruFocus.com
Longleaf Partners Believe HRT Could Be Their Most Exciting Investment Ever Jun 08 2011 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Nov 10 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Aug 16 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) May 04 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Oct 30 2009 
Arrhythmia Research Technology Inc (HRT) CFO David A Garrison buys 5,000 Shares Sep 17 2009 
Weekly CFO Buys Highlight: Arrhythmia Research Technology, Ultra Clean Holdings, Pixelworks, Hospira Aug 16 2009 
Arrhythmia Research Technology Inc (HRT) CFO David A Garrison buys 5,000 Shares Aug 12 2009 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Aug 04 2009 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... Mar 22 2017
Arrhythmia Research Technology, Inc. Reports 2016 Fourth Quarter and Year End Results Mar 22 2017
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or... Mar 14 2017
Arrhythmia Research Technology, Inc. Reports Company Name and Ticker Symbol Changes Mar 09 2017
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Change in Directors or Principal... Jan 03 2017
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Change in Directors or Principal... Dec 06 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Entry into a Material Definitive... Nov 21 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Financials Nov 17 2016
ETFs with exposure to Arrhythmia Research Technology, Inc. : November 16, 2016 Nov 16 2016
Arrhythmia Research Technology, Inc. :HRT-US: Earnings Analysis: Q3, 2016 By the Numbers : November... Nov 11 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... Nov 09 2016
Arrhythmia Research Technology, Inc. Reports 2016 Third Quarter Results Nov 09 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Entry into a Material Definitive... Oct 17 2016
ETF’s with exposure to Arrhythmia Research Technology, Inc. : September 27, 2016 Sep 27 2016
Arrhythmia Research Technology, Inc. :HRT-US: Earnings Analysis: Q2, 2016 By the Numbers : August... Aug 15 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... Aug 11 2016
Arrhythmia Research Technology, Inc. Reports 2016 Second Quarter Results Aug 11 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Submission of Matters to a Vote of... Jun 01 2016
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial... May 25 2016
Arrhythmia Research Technology, Inc. :HRT-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)